SPONSOR

University Hospital, Basel, Switzerland

Total Trials

Recruiting

Phases

Phase 1, Phase 3, Phase 4

Conditions studied: Dental Plaque Oral Biofilm Peri-implantitis Ventral Hernia Incisional Hernia Abdominal Wall Defect Brain Death Adults Distal Radius Fracture Periprocedural Vessel Perforation

University Hospital, Basel, Switzerland is a clinical research sponsor with 21 registered studies on ClinicalTrials.gov, of which 21 are actively recruiting participants. Research covers conditions including Dental Plaque, Oral Biofilm, Peri-implantitis, Ventral Hernia.

The trial portfolio spans Phase 1, Phase 3, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — University Hospital, Basel, Switzerland

How many clinical trials has University Hospital, Basel, Switzerland sponsored?

ClinicalMetric currently tracks 21 clinical trials sponsored by University Hospital, Basel, Switzerland, of which 21 are actively recruiting participants. These trials cover conditions including Dental Plaque, Oral Biofilm, Peri-implantitis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does University Hospital, Basel, Switzerland research focus on?

University Hospital, Basel, Switzerland clinical trials span Dental Plaque, Oral Biofilm, Peri-implantitis, Ventral Hernia, Incisional Hernia, and additional conditions. The research pipeline includes Phase 1, Phase 3, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a University Hospital, Basel, Switzerland clinical trial?

To participate in a University Hospital, Basel, Switzerland trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all University Hospital, Basel, Switzerland trials with current recruitment status updated daily.

University Hospital, Basel, Switzerland

Frequently Asked Questions — University Hospital, Basel, Switzerland

Clinical Trials by University Hospital, Basel, Switzerland

Investigation of Biofilm Formation on Temporary push-on Rings of Implant Crowns

oPen Versus RobotIc retrOmuscular Repair in Medium to Large Ventral Hernias

Pupillometric Evaluation in Patients Declared Brain Dead - a Prospective Quality Control Study

Fracture Registry University Hospital Basel

PeRforation EVents During ENdovascular Therapy for Acute Ischemic Stroke

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

The Use of a Pacifier to Correct Malocclusions in Young Children

Oxytocin in Postmenopausal Women

SteamOne - Prospective Database for Rezum Water Vapor Therapy of the Prostate

Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia

Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage

Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants

Canakinumab for the Treatment of Postprandial Hypoglycemia

Swiss Atrial Fibrillation Pulmonary Vein Isolation Registry

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants

Virtual Reality Aggression Prevention Training (VRAPT) for (Forensic) Psychiatric Patients

Risk of Recurrent CeAD After Pregnancy

Identification of Hepatic Fibrosis Using 4D-MRI

Alternative Prophylaxis in Female Recurrent Urinary Tract Infections

Mechanisms of Maternal Immune Tolerance in Early Pregnancy

Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study